Abraham Van Wyk

Path breaking solutions to large unmet needs in Antimicrobial resistance (AMR) and immuno-oncology. Making highly differentiated assets, affordable and accessible to all of humanity.

WE’RE NOT THE BIGGEST, BUT WE’LL TREAT YOU AS OUR BIGGEST! TCD Outcomes Research (previously HEXOR) is a fully fledged, full service, outcomes research company serving healthcare companies globally and forms part of the TCD group. We specialise in late phase health outcomes research by studying the real world value of healthcare solutions and its economic and financial impact. When you partner with us you’ll receive skillset on a continuum of your needs, be it market access, medical, clinical, regulatory, sales or marketing. Convert scientific evidence related to efficacy, safety and quality into a market approach that focuses on real world evidence (RWE) to communicate the value of your product to your stakeholders. We provide Dynamic Solutions to Dynamic Questions™. These solutions include: Dynamic e-Registries™, Dynamic Pharmacovigilence™, Dynamic post marketing surveillance™, Pharmacoeconomics, patient reported outcomes, value stories and related services.

BUILT LOCALLY... TRUSTED GLOBALLY... In the fast-paced world of clinical research, getting medicines to market quickly and effectively is paramount. Clinical research organisations (CROs) face the challenge of conducting clinical trials in an affordable and efficient manner. However, existing methods and tools often fall short, being inflexible, slow, expensive, and lacking accuracy. Furthermore, there is a significant gap in credible and capable local solutions to support clinical trials. CROs who fail to perform effective clinical trials run the risk of not launching their products on time, losing significant market share and in some cases, even forfeiting the patent of their products. nuvoteQ is a trusted provider of digital technology solutions in the clinical and pharmaceutical research space. Based in Africa, we have developed a range of software products that are trusted by leading organisations worldwide. Our mission is to deliver cost-effective, flexible, and accessible software solutions with precise and high-quality results. nuvoteQ offers a range of powerful software products designed to empower clinical and pharmaceutical research organisations. With a proven track record and successful collaborations with industry giants, nuvoteQ has gained the trust of our clients. They rely on us to deliver exceptional service and results, allowing us to foster long-term partnerships. Additionally, we have established public partnerships, including our affiliation with the Gates Foundation. Our global footprint spans five continents and over 40 countries, reflecting the breadth of our reach. Its worth noting that all our work and platforms are FDA-approved, ensuring regulatory compliance and quality assurance.

GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type 1 invariant NKT (iNKT) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 NKT agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.

FHI Clinical is a full-service contract research organization (CRO) with the global expertise, responsive approaches and proven solutions to manage complex clinical research around the world. Benefitting from our 50+ year history of clinical research, our team of approximately 450 global staff has worked on studies in nearly 75 countries. As problem solvers, forward thinkers and on-the-ground members of those communities, we’re dedicated to helping you find solutions to the research challenges that have kept life-saving medicines from at-risk populations. Visit fhiclinical.com or contact us at info@fhiclinical.com or 919.321.3321 to learn how we can put our diverse clinical and operational expertise to work for you.

Metanoia: Where Regeneration Takes Center Stage At Metanoia, were rewriting the future of healthcare. Were pioneering a revolutionary approach to regenerative medicine that targets the root cause of chronic and age-related diseases. Imagine harnessing the bodys natural healing power to fight illness. Thats the essence of our functional cell regeneration technology. By leveraging insights from cancer biology and genomics, we activate cellular competition, promoting the survival of healthy cells while eliminating diseased ones. This isnt just symptom management – its true transformation. Our first-in-class regenerative therapeutics, targeting a metabolic pathway, offer a beacon of hope for millions struggling with conditions like diabetes. Metanoia stands apart: *We address the root cause* Unlike traditional approaches that manage symptoms, we target the underlying mechanisms of disease, paving the way for potential cures. *Data-driven innovation* Our approach is meticulously researched and backed by robust data, ensuring we translate scientific breakthroughs into real-world impact. *Next-generation solutions* We harness the power of cutting-edge technologies like genomics and functional cell biology to unlock the bodys untapped potential. Ready to join Metanoia’s regeneration revolution? *Visit our website to discover how Metanoia is changing the game: www.Metanoia.bio *Connect with us here on LinkedIn to explore partnership opportunities.

Path breaking solutions to large unmet needs in Antimicrobial resistance (AMR) and immuno-oncology. Making highly differentiated assets, affordable and accessible to all of humanity.

WE’RE NOT THE BIGGEST, BUT WE’LL TREAT YOU AS OUR BIGGEST! TCD Outcomes Research (previously HEXOR) is a fully fledged, full service, outcomes research company serving healthcare companies globally and forms part of the TCD group. We specialise in late phase health outcomes research by studying the real world value of healthcare solutions and its economic and financial impact. When you partner with us you’ll receive skillset on a continuum of your needs, be it market access, medical, clinical, regulatory, sales or marketing. Convert scientific evidence related to efficacy, safety and quality into a market approach that focuses on real world evidence (RWE) to communicate the value of your product to your stakeholders. We provide Dynamic Solutions to Dynamic Questions™. These solutions include: Dynamic e-Registries™, Dynamic Pharmacovigilence™, Dynamic post marketing surveillance™, Pharmacoeconomics, patient reported outcomes, value stories and related services.

BUILT LOCALLY... TRUSTED GLOBALLY... In the fast-paced world of clinical research, getting medicines to market quickly and effectively is paramount. Clinical research organisations (CROs) face the challenge of conducting clinical trials in an affordable and efficient manner. However, existing methods and tools often fall short, being inflexible, slow, expensive, and lacking accuracy. Furthermore, there is a significant gap in credible and capable local solutions to support clinical trials. CROs who fail to perform effective clinical trials run the risk of not launching their products on time, losing significant market share and in some cases, even forfeiting the patent of their products. nuvoteQ is a trusted provider of digital technology solutions in the clinical and pharmaceutical research space. Based in Africa, we have developed a range of software products that are trusted by leading organisations worldwide. Our mission is to deliver cost-effective, flexible, and accessible software solutions with precise and high-quality results. nuvoteQ offers a range of powerful software products designed to empower clinical and pharmaceutical research organisations. With a proven track record and successful collaborations with industry giants, nuvoteQ has gained the trust of our clients. They rely on us to deliver exceptional service and results, allowing us to foster long-term partnerships. Additionally, we have established public partnerships, including our affiliation with the Gates Foundation. Our global footprint spans five continents and over 40 countries, reflecting the breadth of our reach. Its worth noting that all our work and platforms are FDA-approved, ensuring regulatory compliance and quality assurance.